The Filtrate (minus Samira) gather to talk about MENTOR the randomized trial of Rituximab versus cyclosporin for the treatment of idiopathic membranous nephropathy.

Cast:

Joel Topf

Jennie Lin

Matt Sparks

Swapnil Hiremath

Show Notes:

NephJC Coverage of MENTOR: http://www.nephjc.com/news/mentor

MENTOR: https://www.nejm.org/doi/full/10.1056/NEJMoa1814427

KDIGO Membranous recommendations: https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2012-GN-Guideline-English.pdf

2017 Kidney Week Abstract: https://www.asn-online.org/education/kidneyweek/2017/program-abstract.aspx?controlId=2831149

PEXIVAS: http://www.nephjc.com/news/pexivasearly

Heymann Nephritis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042693/

Susan Quaggin: https://www.feinberg.northwestern.edu/faculty-profiles/az/profile.html?xid=26269

Manasi Bapat on non-inferiority trials: http://www.nephjc.com/news/2019/7/8/understanding-the-vortex-of-non-inferiority-trials

Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan: https://www.sciencedirect.com/science/article/pii/S0085253815498503

Nice review of Membranous by Alfaadhel and Cattrran that purports to say than CNI are the standard therapy for idiopathic membranous. (It doesn’t) https://www.ncbi.nlm.nih.gov/pubmed/27536673?dopt=Abstract

Pablo Garcia saves the day: https://twitter.com/PabloGarciaMD/status/1148767319323099136?s=20

Larry beck’s land mark study demonstrating antiPLA2r as the antigen in idiopathic membranous. https://www.nejm.org/doi/full/10.1056/NEJMoa0810457

GEMRITUX Study: https://www.ncbi.nlm.nih.gov/pubmed/27352623

Jennie Lin’s How to Be a Nephrology Fellow, Choose Your Own Adventure: https://twitter.com/jenniejlin/status/1156329711057981442?s=20

CJASN How to Review a Paper Podcast: https://www.asn-online.org/media/podcast/CJASN/2019_07_23_How_to_Write_a_Cons.mp3